四价灭活流感疫苗不同剂量在6-35月龄健康婴幼儿中的耐受性、安全性和初步免疫原性评估:单中心、剂量递增、开放标签I期临床试验
本研究为单中心、剂量递增、开放标签I期临床试验,60名6-35月龄健康婴幼儿随机分为低剂量组(0.25 mL/剂)和高剂量组(0.5 mL/剂),间隔28天肌内接种两剂。两组总不良反应率分别为23.3%和20.0%,无统计学差异(P>0.05);高剂量组对H3N2和B/Yamagata株的GMT和GMI提示可能优于低剂量组。结论为两组耐受性和安全性良好,高剂量组对某些抗原的免疫应答显示潜在优势,但样本量小且排除高危人群,需进一步多中心、大样本III期临床试验验证剂量效应的临床意义。
要点
- 低剂量组(0.25 mL/剂)总不良反应率23.3%,高剂量组(0.5 mL/剂)20.0%,两组无统计学差异(P>0.05)。
- 高剂量组发生1例3级局部不良反应(注射部位红斑),其余为1-2级轻度反应,无与疫苗相关的严重不良事件。
- 接种两剂后,高剂量组针对H3N2和B/Yamagata株的GMT和GMI提示可能优于低剂量组(P<0.05);易感人群中高剂量组H3N2的GMT升高更显著(31.7 vs. 13.2,P=0.0482)。
核心结论
- 低剂量组和高剂量组IIV4在6-35月龄婴幼儿中均显示出良好的耐受性和安全性,高剂量组对某些抗原的免疫应答显示潜在优势。
- 由于样本量小和排除高危人群等局限性,需进一步多中心、大样本III期临床试验验证剂量效应的临床意义,并为幼儿流感防控策略提供证据。
研究设计与样本
- 单中心、剂量递增、开放标签I期临床试验,60名6-35月龄健康婴幼儿随机分为低剂量组(0.25 mL/剂)和高剂量组(0.5 mL/剂)。
- 参与者间隔28天接受两剂肌内注射。
- 试验注册号:CXSL1800038。
主要发现
- 总不良反应率低剂量组为23.3%,高剂量组为20.0%,两组无统计学差异(P>0.05)。
- 高剂量组发生1例3级局部不良反应(注射部位红斑),其余为1-2级轻度反应;无与疫苗相关的严重不良事件。
- 接种两剂后,全人群中高剂量组针对H3N2和B/Yamagata流感株的GMT和GMI提示可能优于低剂量组(P<0.05)。
- 接种前易感人群中,高剂量组针对H3N2的GMT升高更显著(31.7 vs. 13.2,P=0.0482)。
- 两组接种两剂后的血清转化率、GMT和GMI均显著高于接种一剂后(P<0.05),高剂量组显示出更明显的应答增强趋势。
局限性
- 样本量小。
- 排除高危人群。
- 需进一步多中心、大样本III期临床试验验证剂量效应的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to evaluate the tolerability, safety, and preliminary immunogenicity of quadrivalent influenza virus split vaccine (IIV4) in healthy infants and young children aged 6-35 months across different dosages. Employing a single-center, dose-escalation, open-label Phase I clinical trial design, 60 participants were randomly divided into a low-dose group (0.25 mL per dose) and a high-dose group (0.5 mL per dose). Participants received two intramuscular doses administered 28 days apart. Safety results: The overall adverse reaction rates were 23.3 % in the low-dose group and 20.0 % in the high-dose group, with no statistical difference (P > 0.05). One case of grade 3 local adverse reaction (erythema at the injection site) occurred in the high-dose group, and the remaining were mild reactions of grade 1-2. No severe adverse events were related to the vaccine. Immunogenicity results: Total population: After two doses, the GMT and GMI against H3N2 and B/Yamagata influenza strains in the high-dose group suggested a potential superiority over the low-dose group (P < 0.05). Pre-vaccination susceptible population: The high-dose group exhibited a more significant increase in GMT against H3N2 (31.7 vs. 13.2, P = 0.0482). Additionally, both groups showed significantly higher seroconversion rates, GMT, and GMI after two doses compared to one dose (P < 0.05), confirming that the two-dose schedule effectively enhances immune responses. Notably, the high-dose group demonstrated a more pronounced trend of response enhancement. Conclusion: Both the low-dose group and high-dose group IIV4 demonstrated good tolerability and safety in infants and young children aged 6-35 months. The high-dose group showed a potential advantage in immune responses to certain antigens. However, due to limitations such as the small sample size and exclusion of high-risk populations, further multi-center, large-sample Phase III clinical trials are needed to validate the clinical significance of the dose effect and provide evidence for influenza prevention and control strategies in young children. Trial registration: CXSL1800038.
引用
- Zhu Y, Si M, Wang L, et al. Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial. Vaccine. 2025. PMID: 41207071. doi:10.1016/j.vaccine.2025.127962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。